Poor pretransplantation minimal residual disease clearance as an independent prognostic risk factor for survival in myelodysplastic syndrome with excess blasts: A multicenter, retrospective cohort study
Cancer · 2023
DOI: 10.1002/cncr.34762 ↗Kurz gefasst
Multizentrische Studie in der Zeitschrift Cancer, 2023. Verfasst von Ying-Ying Ma und 25 weiteren Autor:innen. Beteiligte Einrichtung: Medical Center of Hematology, Xinqiao Hospital, State Key Laboratory of Trauma, Burn and Combined Injury, Army Medical University, Shapingba District…. Hauptthemen laut MEDLINE: Hematopoietic Stem Cell Transplantation, Leukemia, Myeloid, Acute, Myelodysplastic Syndromes. Die Arbeit wurde bisher 15-mal zitiert (Crossref) und nennt 41 Literaturangaben. Gefördert von: National Natural Science Foundation of China.
Abstract (Originalsprache)
Background
Minimal residual disease (MRD) is an important prognostic factor for survival in adults with acute leukemia. The role of pretransplantation MRD status in myelodysplastic syndrome with excess blasts (MDS‐EB) is unknown. This study retrospectively analyzed the relationship between pretransplantation MRD status and long‐term survival. Materials and Methods Patients with MDS‐EB who underwent allogeneic hematopoietic stem cell transplantation (allo‐HSCT) from March 5, 2005, to November 8, 2020, were included. The relationship between pretransplantation MRD status and long‐term survival was analyzed using univariate and multivariate logistic regression models.
Results
Of 220 patients with MDS‐EB who underwent allo‐HSCT, 198 were eligible for inclusion in this multicenter, retrospective cohort study. Complete remission was attained in 121 (61.1%) patients, and 103 patients underwent detection of MRD pretransplantation, with 67 patients being MRD‐positive and 36 patients being MRD‐negative. The median follow‐up time was 16 months, the median age was 41 years (6–65 years), and 58% of the patients were men. The 3‐year disease‐free survival (DFS) and overall survival (OS) probabilities for all patients were 70.1% and 72.9%, respectively. For patients in complete remission, the 3‐year DFS and OS probabilities were 72.2% and 74.8%, respectively. Further analysis found that the 3‐year DFS rates of MRD‐negative and MRD‐positive patients were 85.6% and 66.5% ( p = .045), respectively, whereas the 3‐year OS rates were 91.3% and 66.4% ( p = .035), respectively. Univariate and multivariate analyses showed that poor pretransplantation MRD clearance was an independent prognostic risk factor for DFS and OS.
Conclusion
Poor pretransplantation MRD clearance is an independent prognostic risk factor for long‐term survival after allo‐HSCT for patients with MDS‐EB. Plain language summary Poor minimal residual disease clearance pretransplanation is an independent prognostic risk factor for long‐term survival after allogeneic hematopoietic stem cell transplantation for patients with myelodysplastic syndrome with excess blasts.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Medical Center of Hematology, Xinqiao Hospital, State Key Laboratory of Trauma, Burn and Combined Injury, Army Medical University, Shapingba District, Chongqing, China.
- Department of Health Statistics, College of Preventive Medicine, Army Medical University, Shapingba District, Chongqing, China.
- Department of Hematology, Xiangya Hospital, Central South University, Changsha, Hunan, China.
- National Clinical Research Center for Geriatric Diseases (Xiangya Hospital), Changsha, Hunan, China.
- Hunan Clinical Medical Research Center of Hematologic Neoplasms, Changsha, Hunan, China.
- National Clinical Research Center for Hematologic Diseases, The First Affiliated Hospital of Soochow University, Soochow, Jiangsu, China.
ORCID-Profile: Cheng Zhang
Förderung
- National Natural Science Foundation of China
Zitieren
APA
Ma, Y. Y., Wei, Z. L., Xu, Y. J., Shi, J. M., Yi, H., Lai, Y. R., Jiang, E. L., Wang, S. B., Wu, T., Gao, L., Gao, L., Kong, P. Y., Wen, Q., Bai, H., Li, Y., Cao, Y. G., Li, Q. C., Zhang, Z. M., Liu, B. C., …, & Zhang, C. (2023). Poor pretransplantation minimal residual disease clearance as an independent prognostic risk factor for survival in myelodysplastic syndrome with excess blasts: A multicenter, retrospective cohort study. Cancer. https://doi.org/10.1002/cncr.34762
Vancouver
Ma YY, Wei ZL, Xu YJ, Shi JM, Yi H, Lai YR, et al. Poor pretransplantation minimal residual disease clearance as an independent prognostic risk factor for survival in myelodysplastic syndrome with excess blasts: A multicenter, retrospective cohort study. Cancer. 2023. doi:10.1002/cncr.34762
BibTeX
@article{Ma2023,
author = {Ma, Ying-Ying and Wei, Ze-Liang and Xu, Ya-Jing and Shi, Ji-Min and Yi, Hai and Lai, Yong-Rong and Jiang, Er-Lie and Wang, San-Bin and Wu, Tao and Gao, Lei and Gao, Li and Kong, Pei-Yan and Wen, Qin and Bai, Hai and Li, Yu and Cao, Yi-Geng and Li, Qiao-Chuan and Zhang, Zhong-Ming and Liu, Bei-Cai and Su, Yi and Lai, Xiao-Yu and Ma, Xia and Cheng, Ting-Ting and Luo, Yi and Zhang, Xi and Zhang, Cheng},
title = {Poor pretransplantation minimal residual disease clearance as an independent prognostic risk factor for survival in myelodysplastic syndrome with excess blasts: A multicenter, retrospective cohort study},
journal = {Cancer},
year = {2023},
doi = {10.1002/cncr.34762}
}
EUVIMED